Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 49

1.

Assessment of a multi-cytokine profile by a novel biochip-based assay allows correlation of cytokine profiles with clinical outcomes in adult recipients of umbilical cord blood transplantation.

Karantanos T, Kim HT, Tijaro-Ovalle NM, Li L, Cutler C, Antin JH, Ballen KK, Ritz J, Politikos I, Boussiotis VA.

Bone Marrow Transplant. 2019 Oct 2. doi: 10.1038/s41409-019-0707-x. [Epub ahead of print] No abstract available.

PMID:
31578466
2.

Reactivation of BK virus after double umbilical cord blood transplantation in adults correlates with impaired reconstitution of CD4+ and CD8+ T effector memory cells and increase of T regulatory cells.

Karantanos T, Kim HT, Tijaro-Ovalle NM, Li L, Cutler C, Antin JH, Ballen K, Marty FM, Tan CS, Ritz J, Politikos I, Boussiotis V.

Clin Immunol. 2019 Oct;207:18-23. doi: 10.1016/j.clim.2019.06.010. Epub 2019 Jun 27.

PMID:
31255803
3.

Acute Myeloid Leukemia Stem Cell Heterogeneity and Its Clinical Relevance.

Karantanos T, Jones RJ.

Adv Exp Med Biol. 2019;1139:153-169. doi: 10.1007/978-3-030-14366-4_9. Review.

PMID:
31134500
4.

Metabolic Targets for Improvement of Allogeneic Hematopoietic Stem Cell Transplantation and Graft-vs.-Host Disease.

Tijaro-Ovalle NM, Karantanos T, Wang HT, Boussiotis VA.

Front Immunol. 2019 Mar 5;10:295. doi: 10.3389/fimmu.2019.00295. eCollection 2019. Review.

5.

Clinical Benefit to an Aurora A Kinase Inhibitor in a Patient with Metastatic Integrase Interactor 1-Deficient Carcinoma.

Karantanos T, Rooper L, Kang Y, Lin CT, Wenga P, Sagorsky S, Lauring J, Kang H.

Oncologist. 2019 Feb;24(2):146-150. doi: 10.1634/theoncologist.2018-0279. Epub 2018 Oct 8.

PMID:
30297384
6.

The absolute lymphocyte count can predict the overall survival of patients with non-small cell lung cancer on nivolumab: a clinical study.

Karantanos T, Karanika S, Seth B, Gignac G.

Clin Transl Oncol. 2019 Feb;21(2):206-212. doi: 10.1007/s12094-018-1908-2. Epub 2018 Jun 13.

PMID:
29948974
7.

Salivary Secretory Carcinoma With a Novel ETV6-MET Fusion: Expanding the Molecular Spectrum of a Recently Described Entity.

Rooper LM, Karantanos T, Ning Y, Bishop JA, Gordon SW, Kang H.

Am J Surg Pathol. 2018 Aug;42(8):1121-1126. doi: 10.1097/PAS.0000000000001065.

PMID:
29683815
8.

The roles of JAK2 in DNA damage and repair in the myeloproliferative neoplasms: Opportunities for targeted therapy.

Karantanos T, Moliterno AR.

Blood Rev. 2018 Sep;32(5):426-432. doi: 10.1016/j.blre.2018.03.007. Epub 2018 Mar 30. Review.

PMID:
29627078
9.

JAK3-mediated phosphorylation of EZH2: a novel mechanism of non-canonical EZH2 activation and oncogenic function.

Karantanos T, Boussiotis VA.

Transl Cancer Res. 2016 Nov;5(Suppl 6):S1208-S1211. doi: 10.21037/tcr.2016.11.11. No abstract available.

10.

Advances in the pathophysiology and treatment of relapsed/refractory Hodgkin's lymphoma with an emphasis on targeted therapies and transplantation strategies.

Karantanos T, Politikos I, Boussiotis VA.

Blood Lymphat Cancer. 2017;7:37-52. doi: 10.2147/BLCTT.S105458. Epub 2017 May 9.

11.

Androgen receptor inhibitor-induced "BRCAness" and PARP inhibition are synthetically lethal for castration-resistant prostate cancer.

Li L, Karanika S, Yang G, Wang J, Park S, Broom BM, Manyam GC, Wu W, Luo Y, Basourakos S, Song JH, Gallick GE, Karantanos T, Korentzelos D, Azad AK, Kim J, Corn PG, Aparicio AM, Logothetis CJ, Troncoso P, Heffernan T, Toniatti C, Lee HS, Lee JS, Zuo X, Chang W, Yin J, Thompson TC.

Sci Signal. 2017 May 23;10(480). pii: eaam7479. doi: 10.1126/scisignal.aam7479.

12.

Pyogenic Liver Abscess Due to Fusobacterium nucleatum in a Patient With Liver Hemangiomas.

Karantanos T, Karanika S, Obiokoye K, Sullivan M, Phillips C, Ananthakrishnan S.

Am J Med Sci. 2017 Apr;353(4):417-418. doi: 10.1016/j.amjms.2016.07.008. Epub 2016 Aug 30. No abstract available.

PMID:
28317637
13.

Targeting DNA Damage Response in Prostate Cancer by Inhibiting Androgen Receptor-CDC6-ATR-Chk1 Signaling.

Karanika S, Karantanos T, Li L, Wang J, Park S, Yang G, Zuo X, Song JH, Maity SN, Manyam GC, Broom B, Aparicio AM, Gallick GE, Troncoso P, Corn PG, Navone N, Zhang W, Li S, Thompson TC.

Cell Rep. 2017 Feb 21;18(8):1970-1981. doi: 10.1016/j.celrep.2017.01.072.

14.

Immunotherapy comes of age: Immune aging & checkpoint inhibitors.

Elias R, Karantanos T, Sira E, Hartshorn KL.

J Geriatr Oncol. 2017 May;8(3):229-235. doi: 10.1016/j.jgo.2017.02.001. Epub 2017 Feb 17. Review.

PMID:
28223073
15.

Epigenetic regulation of cancer biology and anti-tumor immunity by EZH2.

Christofides A, Karantanos T, Bardhan K, Boussiotis VA.

Oncotarget. 2016 Dec 20;7(51):85624-85640. doi: 10.18632/oncotarget.12928. Review.

16.

Angiogenic Factors Correlate with T Cell Immune Reconstitution and Clinical Outcomes after Double-Unit Umbilical Cord Blood Transplantation in Adults.

Politikos I, T Kim H, Karantanos T, Brown J, McDonough S, Li L, Cutler C, Antin JH, Ballen KK, Ritz J, Boussiotis VA.

Biol Blood Marrow Transplant. 2017 Jan;23(1):103-112. doi: 10.1016/j.bbmt.2016.10.013. Epub 2016 Oct 21.

17.

Corrigendum: Regulation of T Cell Differentiation and Function by EZH2.

Karantanos T, Christofides A, Bardhan K, Li L, Boussiotis VA.

Front Immunol. 2016 Sep 14;7:346. doi: 10.3389/fimmu.2016.00346. eCollection 2016.

18.

Uncontrolled diabetes predicts poor response to novel antiandrogens.

Karantanos T, Karanika S, Gignac G.

Endocr Relat Cancer. 2016 Sep;23(9):691-8. doi: 10.1530/ERC-16-0222.

PMID:
27515296
19.

Caveolin-1 regulates hormone resistance through lipid synthesis, creating novel therapeutic opportunities for castration-resistant prostate cancer.

Karantanos T, Karanika S, Wang J, Yang G, Dobashi M, Park S, Ren C, Li L, Basourakos SP, Hoang A, Efstathiou E, Wang X, Troncoso P, Titus M, Broom B, Kim J, Corn PG, Logothetis CJ, Thompson TC.

Oncotarget. 2016 Jul 19;7(29):46321-46334. doi: 10.18632/oncotarget.10113.

20.

Regulation of T Cell Differentiation and Function by EZH2.

Karantanos T, Chistofides A, Barhdan K, Li L, Boussiotis VA.

Front Immunol. 2016 May 3;7:172. doi: 10.3389/fimmu.2016.00172. eCollection 2016. Review. Erratum in: Front Immunol. 2016;7:346.

21.

Fecal Colonization With Extended-spectrum Beta-lactamase-Producing Enterobacteriaceae and Risk Factors Among Healthy Individuals: A Systematic Review and Metaanalysis.

Karanika S, Karantanos T, Arvanitis M, Grigoras C, Mylonakis E.

Clin Infect Dis. 2016 Aug 1;63(3):310-8. doi: 10.1093/cid/ciw283. Epub 2016 May 3. Review. Erratum in: Clin Infect Dis. 2016 Sep 15;63(6):851.

PMID:
27143671
22.

Assessing the cardiovascular risk of hormonal therapy in patients with prostate cancer.

Karantanos T, Karanika S.

Ann Transl Med. 2016 Mar;4(5):99. doi: 10.21037/atm.2016.01.23. No abstract available.

23.

Synbiotics and gastrointestinal function-related quality of life after elective colorectal cancer resection.

Theodoropoulos GE, Memos NA, Peitsidou K, Karantanos T, Spyropoulos BG, Zografos G.

Ann Gastroenterol. 2016 Jan-Mar;29(1):56-62.

24.

Association of CD133 polymorphisms and response to bevacizumab in patients with metastatic colorectal cancer.

Aravantinos G, Isaakidou A, Karantanos T, Sioziou A, Theodoropoulos GE, Pektasides D, Gazouli M.

Cancer Biomark. 2015;15(6):843-50. doi: 10.3233/CBM-150528.

PMID:
26406410
25.

GLIPR1-ΔTM synergizes with docetaxel in cell death and suppresses resistance to docetaxel in prostate cancer cells.

Karanika S, Karantanos T, Kurosaka S, Wang J, Hirayama T, Yang G, Park S, Golstov AA, Tanimoto R, Li L, Thompson TC.

Mol Cancer. 2015 Jun 19;14:122. doi: 10.1186/s12943-015-0395-0.

26.

Understanding the mechanisms of androgen deprivation resistance in prostate cancer at the molecular level.

Karantanos T, Evans CP, Tombal B, Thompson TC, Montironi R, Isaacs WB.

Eur Urol. 2015 Mar;67(3):470-9. doi: 10.1016/j.eururo.2014.09.049. Epub 2014 Oct 8. Review.

27.

Novel anti-androgen receptor signaling agents: Understanding the mechanisms of resistance.

Karanika S, Karantanos T, Yin J, Li L, Thompson TC.

Asian J Urol. 2014 Oct;1(1):30-39. doi: 10.1016/j.ajur.2015.04.004. Epub 2015 Apr 16. Review.

28.

DNA damage response and prostate cancer: defects, regulation and therapeutic implications.

Karanika S, Karantanos T, Li L, Corn PG, Thompson TC.

Oncogene. 2015 May 28;34(22):2815-22. doi: 10.1038/onc.2014.238. Epub 2014 Aug 18. Review.

29.

Quality of life after laparoscopic colectomy for cancer.

Theodoropoulos GE, Karantanos T.

JSLS. 2014 Apr-Jun;18(2):225-35. doi: 10.4293/108680813X13753907291152. Review.

30.

Targeting poly(ADP-ribose) polymerase and the c-Myb-regulated DNA damage response pathway in castration-resistant prostate cancer.

Li L, Chang W, Yang G, Ren C, Park S, Karantanos T, Karanika S, Wang J, Yin J, Shah PK, Takahiro H, Dobashi M, Zhang W, Efstathiou E, Maity SN, Aparicio AM, Li Ning Tapia EM, Troncoso P, Broom B, Xiao L, Lee HS, Lee JS, Corn PG, Navone N, Thompson TC.

Sci Signal. 2014 May 20;7(326):ra47. doi: 10.1126/scisignal.2005070.

31.

Immune response after laparoscopic colectomy for cancer: a review.

Karanika S, Karantanos T, Theodoropoulos GE.

Gastroenterol Rep (Oxf). 2013 Sep;1(2):85-94. doi: 10.1093/gastro/got014. Epub 2013 May 3.

32.

Association of rs1568885, rs1813443 and rs4411591 polymorphisms with anti-TNF medication response in Greek patients with Crohn's disease.

Thomas D, Gazouli M, Karantanos T, Rigoglou S, Karamanolis G, Bramis K, Zografos G, Theodoropoulos GE.

World J Gastroenterol. 2014 Apr 7;20(13):3609-14. doi: 10.3748/wjg.v20.i13.3609.

33.

Systemic GLIPR1-ΔTM protein as a novel therapeutic approach for prostate cancer.

Karantanos T, Tanimoto R, Edamura K, Hirayama T, Yang G, Golstov AA, Wang J, Kurosaka S, Park S, Thompson TC.

Int J Cancer. 2014 Apr 15;134(8):2003-13. doi: 10.1002/ijc.28529. Epub 2013 Nov 1.

34.

Clock genes: their role in colorectal cancer.

Karantanos T, Theodoropoulos G, Pektasides D, Gazouli M.

World J Gastroenterol. 2014 Feb 28;20(8):1986-92. doi: 10.3748/wjg.v20.i8.1986. Review.

35.

Do anastomotic leaks impair postoperative health-related quality of life after rectal cancer surgery? A case-matched study.

Marinatou A, Theodoropoulos GE, Karanika S, Karantanos T, Siakavellas S, Spyropoulos BG, Toutouzas K, Zografos G.

Dis Colon Rectum. 2014 Feb;57(2):158-66. doi: 10.1097/DCR.0000000000000040.

PMID:
24401876
36.

Association of the clock genes polymorphisms with colorectal cancer susceptibility.

Karantanos T, Theodoropoulos G, Gazouli M, Vaiopoulou A, Karantanou C, Stravopodis DJ, Bramis K, Lymperi M, Pektasidis D.

J Surg Oncol. 2013 Dec;108(8):563-7. doi: 10.1002/jso.23434. Epub 2013 Sep 13.

PMID:
24037774
37.

GEMMs shine a light on resistance to androgen deprivation therapy for prostate cancer.

Karantanos T, Thompson TC.

Cancer Cell. 2013 Jul 8;24(1):11-3. doi: 10.1016/j.ccr.2013.06.007. Erratum in: Cancer Cell. 2013 Aug 12;24(2):272.

38.

Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches.

Karantanos T, Corn PG, Thompson TC.

Oncogene. 2013 Dec 5;32(49):5501-11. doi: 10.1038/onc.2013.206. Epub 2013 Jun 10. Review.

39.

Expression of clock genes in patients with colorectal cancer.

Karantanos T, Theodoropoulos G, Gazouli M, Vaiopoulou A, Karantanou C, Lymberi M, Pektasides D.

Int J Biol Markers. 2013 Sep 27;28(3):280-5. doi: 10.5301/jbm.5000033.

PMID:
23712462
40.

Post-colectomy assessment of gastrointestinal function: a prospective study on colorectal cancer patients.

Theodoropoulos GE, Papanikolaou IG, Karantanos T, Zografos G.

Tech Coloproctol. 2013 Oct;17(5):525-36. doi: 10.1007/s10151-013-1008-9. Epub 2013 Apr 19.

PMID:
23605189
41.

Probiotics, prebiotics, synbiotics: is there enough evidence to support their use in colorectal cancer surgery?.

Peitsidou K, Karantanos T, Theodoropoulos GE.

Dig Surg. 2012;29(5):426-38. doi: 10.1159/000345580. Epub 2012 Dec 14. Review.

42.

Prospective evaluation of health-related quality of life after laparoscopic colectomy for cancer.

Theodoropoulos GE, Karantanos T, Stamopoulos P, Zografos G.

Tech Coloproctol. 2013 Feb;17(1):27-38. doi: 10.1007/s10151-012-0869-7. Epub 2012 Oct 13.

PMID:
23065134
43.

Caspase 9 promoter polymorphisms confer increased susceptibility to breast cancer.

Theodoropoulos GE, Michalopoulos NV, Pantou MP, Kontogianni P, Gazouli M, Karantanos T, Lymperi M, Zografos GC.

Cancer Genet. 2012 Oct;205(10):508-12. doi: 10.1016/j.cancergen.2012.08.001. Epub 2012 Sep 13.

PMID:
22981751
44.

Toll-like receptors gene polymorphisms may confer increased susceptibility to breast cancer development.

Theodoropoulos GE, Saridakis V, Karantanos T, Michalopoulos NV, Zagouri F, Kontogianni P, Lymperi M, Gazouli M, Zografos GC.

Breast. 2012 Aug;21(4):534-8. doi: 10.1016/j.breast.2012.04.001. Epub 2012 May 2.

45.

Serotonin transporter and G protein beta 3 subunit gene polymorphisms in Greeks with irritable bowel syndrome.

Markoutsaki T, Karantanos T, Gazouli M, Anagnou NP, Ladas SD, Karamanolis DG.

Dig Dis Sci. 2011 Nov;56(11):3276-80. doi: 10.1007/s10620-011-1726-7. Epub 2011 May 11.

PMID:
21559741
46.

5-HT2A receptor gene polymorphisms and irritable bowel syndrome.

Markoutsaki T, Karantanos T, Gazouli M, Anagnou NP, Karamanolis DG.

J Clin Gastroenterol. 2011 Jul;45(6):514-7. doi: 10.1097/MCG.0b013e318205e13b.

PMID:
21325954
47.

Inflammatory bowel disease: recent advances on genetics and innate immunity.

Karantanos T, Gazouli M.

Ann Gastroenterol. 2011;24(3):164-172. Review.

48.

Current insights in to the pathophysiology of Irritable Bowel Syndrome.

Karantanos T, Markoutsaki T, Gazouli M, Anagnou NP, Karamanolis DG.

Gut Pathog. 2010 May 13;2(1):3. doi: 10.1186/1757-4749-2-3.

49.

Vascular endothelial growth factor and endoglin expression in colorectal cancer.

Dassoulas K, Gazouli M, Theodoropoulos G, Christoni Z, Rizos S, Zisi-Serbetzoglou A, Glava C, Karantanos T, Klonaris C, Karakitsos P.

J Cancer Res Clin Oncol. 2010 May;136(5):703-8. doi: 10.1007/s00432-009-0709-y. Epub 2009 Nov 5.

PMID:
19890661

Supplemental Content

Loading ...
Support Center